Looking for leads, investment insights, or competitive intelligence?
News about Regeneron Pharmaceuticals
Amgen says Repatha sold $271 million in the first half of 2018, despite earlier predictions of multi-billion-dollar sales.
Scientists are ready to move an experimental treatment into phase 1 trials.
“We should only be working on two things, health and the freaking environment.”
But Dupixent's high cost could be a problem.